Cytokinetics to Announce Third Quarter Results on November 4, 2026
Cytokinetics Inc CYTK
News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Cytokinetics to Participate in September Investor Conferences
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics Files Complaint on Patent Issue Against Bristol-Myers Squibb
Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Cytokinetics Gets FDA Approval for Heart Disease Drug Myqorzo
United States